Palpex Pharmaceuticals pvt ltd
Private pharmaceutical manufacturer · Karachi · Pakistan
Karachi pharmaceutical manufacturer established in 2017 with general and cephalosporin oral and injectable manufacturing capabilities.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Palpex Pharmaceuticals (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- Plot FD-46-A8, Street 1, Sector 38, Korangi Creek Industrial Park, Karachi 74900, Pakistan · 74900
- Website
- palpex.com ↗
- Phone
- +92 21 38893900-02
- info@palpex.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| B-Art 20 | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 16's | 082295 | PKR 592.04 | PKR 37.00/tablet | 7% below median |
| B-Art Dry | Artemether + Lumefantrine | 15 mg/5 mL + 90 mg/5 mL | Dry suspension | 60ml | 082948 | PKR 326.37 | PKR 5.44/mL | 5% below median |
| B-Art Dry | Artemether + Lumefantrine | 15 mg/5 mL + 90 mg/5 mL | Dry suspension | 30ml | 082948 | PKR 166.51 | PKR 5.55/mL | Near median |
| B-Art DS 40 | Artemether + Lumefantrine | 40 mg + 240 mg | Tablet | 8's | 082296 | PKR 488.43 | PKR 61.05/tablet | Near median |
| B-Art Forte | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 6,s | 082297 | PKR 610.54 | PKR 101.76/tablet | 7% below median |
| B-Ther | Artemether | 80 mg/mL | Injection | 1mlx5's | 089107 | PKR 888.05 | PKR 177.61/mL | 6% below median |
| Cipropal | Ciprofloxacin | 250 mg | Tablet | 10's | 082931 | PKR 240.52 | PKR 24.05/tablet | 5% below median |
| Cipropal | Ciprofloxacin | 500 mg | Tablet | 10's | 082932 | PKR 397.77 | PKR 39.78/tablet | 7% below median |
| Cipropal | Ciprofloxacin | 200 mg/100 mL | Solution for infusion | 100ml | 082949 | PKR 185.01 | PKR 1.85/mL | No comparator |
| Cynith | Ceftriaxone | 250 mg | Injection | 1's | 082956 | PKR 186.86 | PKR 186.86/vial/unit | Near median |
| Cynith | Ceftriaxone | 500 mg | Injection | 1's | 082957 | PKR 314.51 | PKR 314.51/vial/unit | Near median |
| Cynith | Ceftriaxone | 500 mg | Injection | 1's | 082960 | PKR 314.51 | PKR 314.51/vial/unit | Near median |
| Cynith | Ceftriaxone | 1 g | IV injection | 1's | 082961 | PKR 593.88 | PKR 593.88/vial/unit | Near median |
| D-Tan | Cholecalciferol | 5 mg/mL (200,000 IU/mL) | Injection | 1's | 082971 | PKR 203.53 | PKR 203.53/vial/unit | 9% below median |
| D-Tan | Cholecalciferol | 200,000 IU/mL | Injection | 5's | 082971 | PKR 864.00 | PKR 172.80/vial/unit | 23% below median |
| Fincef | Cefixime | 400 mg | Capsule | 5's | 082943 | PKR 564.17 | PKR 112.83/capsule | Near median |
| Fincef Dry | Cefixime | 100 mg/5 mL | Dry suspension | 30ml | 082946 | PKR 314.83 | PKR 10.49/mL | Near median |
| Fincef DS Dry | Cefixime | 200 mg/5 mL | Dry suspension | 30ml | 092895 | PKR 385.29 | PKR 12.84/mL | Near median |
| Keynom | Omeprazole | 20 mg | Capsule | 14's | 082936 | PKR 266.42 | PKR 19.03/capsule | Near median |
| Keynom | Omeprazole | 40 mg | Powder for solution for IV infusion | 1's | 082953 | PKR 555.02 | PKR 555.02/vial/unit | No comparator |
| Keynom | Omeprazole | 40 mg | Solution for infusion | 1's | 082953 | PKR 555.02 | PKR 555.02/vial/unit | 15% above median |
| KeynomCapsule | Omeprazole | 40 mg | Capsule | 2x7's | 082937 | PKR 462.53 | PKR 33.04/capsule | Near median |
| Ncopenem Injection 1g IVRegistry verified | Meropenem as Trihydrate Blended with Anhydrous Sodium Carbonate (Sterile) | — | — | — | 108954Official source ↗ | No indexed price | — | — |
| Ncopenem Injection 500mg IVRegistry verified | Meropenem as Trihydrate Blended with Anhydrous Sodium Carbonate (Sterile) | — | — | — | 108953Official source ↗ | No indexed price | — | — |
| Palfer | Iron sucrose | 100 mg/5 mL | Injection | 5mlx5's | 082968 | PKR 2,728.90 | PKR 109.16/mL | 33% above median |
| Palflox | Levofloxacin | 250 mg | Tablet | 10's | 082929 | PKR 462.53 | PKR 46.25/tablet | Near median |
| Palflox | Levofloxacin | 500 mg | Tablet | 10's | 082930 | PKR 769.64 | PKR 76.96/tablet | Near median |
| Palflox | Levofloxacin | 500 mg/100 mL | Solution for infusion | 100ml | 082950 | PKR 462.53 | PKR 4.63/mL | No comparator |
| Palfotax | Cefotaxime | 250 mg | Injection | 1's | 082962 | PKR 105.67 | PKR 105.67/vial/unit | Near median |
| Palfotax | Cefotaxime | 500 mg | Injection | 1's | 082963 | PKR 159.25 | PKR 159.25/vial/unit | Near median |
| Palfotax | Cefotaxime | 1 g | IV injection | 1's | 082964 | PKR 286.42 | PKR 286.42/vial/unit | 15% above median |
| Palmizol | Metronidazole | 500 mg/100 mL | Injection | 100ml | 082951 | PKR 144.31 | PKR 1.44/mL | 5% above median |
| Palthro | Azithromycin | 250 mg | Capsule | 6's | 082938 | PKR 283.06 | PKR 47.18/capsule | Near median |
| Palthro | Azithromycin | 200 mg/5 mL | Dry suspension | 30ml | 082947 | PKR 598.33 | PKR 19.94/mL | 6% below median |
| Palthro | Azithromycin | 200 mg/5 mL | Dry suspension | 15ml | 082947 | PKR 305.27 | PKR 20.35/mL | Near median |
| Palthro | Azithromycin | 500 mg | Powder for solution for infusion | 1's | 082955 | PKR 370.03 | PKR 370.03/vial/unit | No comparator |
| Palthro | Azithromycin | 500 mg | Solution for infusion | 1's | 082955 | PKR 370.03 | PKR 370.03/vial/unit | No comparator |
| Palxamic | Tranexamic acid | 250 mg | Capsule | 20's | 082941 | PKR 240.52 | PKR 12.03/capsule | 18% above median |
| Palxamic | Tranexamic acid | 500 mg/5 mL | Injection | 5mlx5's | 096225 | PKR 786.29 | PKR 31.45/mL | 50% above median |
| Palxamic | Tranexamic acid | 500 mg | Capsule | 20's | 096997 | PKR 462.53 | PKR 23.13/capsule | 12% above median |
| Palzidime | Ceftazidime | 250 mg | Injection | 1's | 089354 | PKR 159.94 | PKR 159.94/vial/unit | Near median |
| Palzidime | Ceftazidime | 500 mg | IV/IM injection | 1's | 089355 | PKR 243.30 | PKR 243.30/vial/unit | Near median |
| Palzidime | Ceftazidime | 1 g | Injection | 1's | 089356 | PKR 456.99 | PKR 456.99/vial/unit | Near median |
| Palzon | Ceftriaxone | 250 mg | IV injection | 1's | 082959 | PKR 186.86 | PKR 186.86/vial/unit | Near median |
| Sunatex | Artesunate | 120 mg | IM/IV injection | 1's | 089353 | PKR 370.03 | PKR 370.03/vial/unit | No comparator |
| Sunatex | Artesunate | 60 mg | IM/IV injection | 1's | 100098 | PKR 211.16 | PKR 211.16/vial/unit | No comparator |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.